RESUMO
OBJECTIVE: To study effects of microRNA-98 (miR-98) on osteogenic differentiation of mesenchymal stem cells (MSCs). PATIENTS AND METHODS: We predicted target gene of miR-98 with software test, and detected expression changes of miR-98, as well as its target gene HMGA2, in the process of osteogenic differentiation of mesenchymal stem cells. After transfection of miR-98 mimic and HMGA2 siRNA, we induced osteogenic differentiation and detected expression changes of osteogenic differentiation markers (RUNX2, ALP, OCN, and BSP). RESULTS: MiR-98 combined directly with target gene HMGA2 and inhibited its expression. During the process of osteogenic differentiation, expression of miR-98 was up-regulated, while HMGA2 expression was down-regulated. In addition, the expression of osteogenesis maker genes increased in cells being transfected with miR-98 mimics and HMGA2 siRNA. CONCLUSIONS: MiR-98 can promote osteogenic differentiation of mesenchymal stem cells by targeting gene HMGA2.
Assuntos
Diferenciação Celular/genética , Regulação da Expressão Gênica , Proteína HMGA2/genética , Células-Tronco Mesenquimais/citologia , MicroRNAs/genética , Osteogênese/genética , Células Cultivadas , Regulação para Baixo , Humanos , Células-Tronco Mesenquimais/metabolismo , RNA Interferente Pequeno/genética , Transfecção , Regulação para CimaRESUMO
All melanoma suspected patients must be confirmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 containing therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 containing therapy. Up to 10 years follow up is reasonable for melanoma patients with dermatologic examinations and physical exams (AU)
No disponible
Assuntos
Humanos , Melanoma/terapia , Neoplasias Cutâneas/terapia , Guias de Prática Clínica como Assunto , Biópsia de Linfonodo Sentinela , Metástase Neoplásica/terapia , Quimioterapia Adjuvante/métodos , Recidiva Local de Neoplasia/terapiaRESUMO
All melanoma patients must be confirmed histologically and resected according to Breslow. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon must be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 therapy. Up to 10 years follow up is recommended for melanoma patients with dermatologic examinations and physical exams (AU)
No disponible
